Skip to main content
Caplight Logo









NeRRe Therapeutics

NeRRe Therapeutics

Private
StevenageHealthcare & Life Scienceshttps://nerretherapeutics.com/

Last Round

Series B

Extension

Jul 7, 2021

Total Funding Raised

$74.73M

Company Overview

NeRRe Therapeutics is a clinical-stage biotechnology company that develops a portfolio of neurokinin receptor antagonists to treat debilitating conditions caused by neuronal hypersensitivity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyclinical-stage pharmaneurokinin receptor antagonistNK1 receptor antagonistchronic cough treatmentdrug discoveryclinical trialsneurogenic disordersbiotech startupdrug developmentsmall molecule drugpharma pipelinebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NeRRe Therapeutics Comparables

Compare NeRRe Therapeutics with similar companies based on industry and business-model similarity.

NeRRe Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Axalbion
85%
Nocion Therapeutics
81%
Melius Pharma
79%

NeRRe Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJul 7, 2021
Series BJan 5, 2017
Series ADec 19, 2012

Key People

Founding team and executive leadership

Mike Trower

Co-Founder Chief Scientific Officer

Founding Team

NeRRe Therapeutics Investors

Notable investors and investment history

NeRRe Therapeutics investors
InvestorRounds
Forbion Capital PartnersSeries B Extension, Series B
ForbionSeries B Extension, Series B
Future FundSeries B Extension
Advent Life SciencesSeries B Extension, Series B
Fountain Healthcare PartnersSeries B Extension, Series B
OrbiMedSeries B Extension, Series B
Advent Venture PartnersSeries A

NeRRe Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

NeRRe Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about NeRRe Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersStevenage
Employee Range9
Year Founded2012
Last FundingJul 7, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?